MT-1 (Melanotan-1) Research Peptide | Onderzoek naar Melanocortine-Receptoren en Huidbiologie

MT-1 (Melanotan-1) Research Peptide | Research on Melanocortin Receptors and Skin Biology

MT-1 (Melanotan-1) Research Peptide | Research on Melanocortin Receptors and Skin Biology

What is MT-1?

MT-1 (Melanotan-1 or Afamelanotide analog) is a synthetic peptide studied for its interaction with melanocortin receptors. Scientific research focuses on pigmentation, UV response, and skin biology.

MT-1 is intended exclusively for Research Use Only (RUO) and not for human use.


How does MT-1 work?

MT-1 primarily binds to the MC1R (Melanocortin-1 Receptor). This leads scientists to investigate processes involved in:

  • melanin synthesis
  • pigmentation
  • UV response
  • oxidative stress
  • skin biology

Research on pigmentation

An important research area is the regulation of eumelanin and the response of pigment cells to UV radiation.

This helps researchers better understand how the skin's natural protective mechanisms function.


Research on UV damage

Preclinical studies investigate the possible influence of melanocortin signaling pathways on:

  • DNA repair
  • oxidative stress
  • protection against UV damage
  • skin aging

Research on inflammatory processes

Besides pigmentation, it is being investigated whether activation of melanocortin receptors affects inflammatory pathways within various tissues.

Additional research is necessary for these applications.


Current state of research

Available for MT-1:

  • extensive laboratory studies
  • animal research
  • selected clinical trials within specific medical indications

Many research questions are still the subject of ongoing studies.


Conclusion

MT-1 remains an important research peptide within dermatology and melanocortin biology. Especially pigmentation, UV response, and skin research are active scientific research areas.

Research Use Only. Not intended for human use.


 

Back to blog

Leave a comment

Please note, comments need to be approved before they are published.